Heron Therapeutics, Inc.
HRTX
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.20M | 38.90M | 40.78M | 32.81M | 36.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.20M | 38.90M | 40.78M | 32.81M | 36.02M |
| Cost of Revenue | 12.79M | 10.74M | 13.41M | 13.92M | 14.95M |
| Gross Profit | 24.41M | 28.17M | 27.38M | 18.89M | 21.07M |
| SG&A Expenses | 26.05M | 25.01M | 23.20M | 23.35M | 27.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.84M | 35.75M | 36.61M | 37.27M | 42.47M |
| Operating Income | -1.64M | 3.15M | 4.17M | -4.46M | -6.45M |
| Income Before Tax | -2.38M | 2.64M | 3.66M | -4.85M | -9.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.38M | 2.64M | 3.66M | -4.85M | -9.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.38M | 2.64M | 3.66M | -4.85M | -9.24M |
| EBIT | -1.64M | 3.15M | 4.17M | -4.46M | -6.45M |
| EBITDA | -1.03M | 3.71M | 4.75M | -3.88M | -5.80M |
| EPS Basic | -0.02 | 0.02 | 0.02 | -0.03 | -0.06 |
| Normalized Basic EPS | -0.01 | 0.01 | 0.02 | -0.02 | -0.04 |
| EPS Diluted | -0.02 | 0.01 | 0.02 | -0.03 | -0.06 |
| Normalized Diluted EPS | -0.01 | 0.01 | 0.02 | -0.02 | -0.04 |
| Average Basic Shares Outstanding | 154.02M | 153.49M | 153.15M | 152.83M | 152.31M |
| Average Diluted Shares Outstanding | 154.02M | 196.92M | 153.15M | 152.83M | 152.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |